BioSpace News Archive

Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi PARIS– December 16, 2021 - On December 15, 2021, the Board of Directors appointed Gilles Schnepp, an independent director of Sanofi, as Chairman of the Appointments, Governance and CSR Committee.

Biophytis SA announces to enter into first regulatory activities to advance Sarconeos development in sarcopenia from Phase 2 to Phase 3 development, with a Type B/End-of-Phase 2 meeting withFDA, USA, on January 24th, 2022, to discuss SARA-INT results and the Phase 3 protocol design.

The demand within the global market for pharmaceutical CDMO services has been rising on account of the need develop safe and effective drugs for the treatment of multiple diseases and disorders.

The demand within the global naloxone market has been rising on account of the efforts of the pharmaceutical industry to prevent the ill-effects of drugs overdose.

Gestational diabetes can be defined as a type of diabetes that affects pregnant women. It is usually a temporary condition which develops during pregnancy and subsides after the birth of the baby.

Colorectal cancer, commonly known as colon cancer, rectal cancer, or bowel cancer, is the development of cancerous cells in the colon or rectum, which are the parts of large intestine.

Antibacterial drugs constitute chemicals either obtained from a natural source or synthesized in a laboratory that kill or inhibit the growth of various bacterial strains.

Innate Pharma SA announced that the first patient was dosed in a Phase 1/2 clinical trial, evaluating IPH6101/SAR443579, the first NKp46/CD16-based NK cell engager, in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia or high risk-myelodysplastic syndrome.

BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, announces the signature of a new agreement with H&T Presspart, whereby H&T Presspart is licenced to sell and promote BIOCORP’s InspairTM smart add-on device for metered-dose inhalers.

Nicox SA, an international ophthalmology company, announced that the first patient has been screened in China in the ongoing Denali Phase 3 clinical trial, opening the way for New Drug Application submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma.